معلومات الادوية وادلة العلاج

2026-07-08 17:07发布于上海转化医学网官方账号 这项名为NCT04578613的III期临床试验共纳入192例符合条件的初治CLL/SLL患者，按1:1比例随机分配至奥布替尼单药组（91例）和苯丁酸氮芥联合利妥昔单抗组（101例）。截至2024年5月17日的数据截止日，中位随访时间为21.4个月。

Esbriet is a medicine used to treat adults with idiopathic pulmonary fibrosis (IPF).

Research News - World's First Clinical Trial Showing Lubiprostone Aids Kidney Function tohoku.ac.jp

Antiretroviral Therapy and HIV Drug Resistance Pan American Health Organization (PAHO)

Fact sheet: HIV drug resistance World Health Organization (WHO)

Drugs and antibodies: biological therapy against Aids is getting closer Il Sole 24 ORE